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Abstract
Background Manganese superoxide dismutase (MnSOD)
plays a critical role in the detoxification of mitochondrial reactive
oxygen species, constituting a major cellular defense
mechanism against agents that induce oxidative stress. A
genetic polymorphism in the mitochondrial targeting sequence
of this gene has been associated with increased cancer risk and
survival in breast cancer. This base pair transition (-9 T > C)
leads to a valine to alanine amino acid change in the
mitochondrial targeting sequence. A polymorphism has also
been identified in the proximal region of the promoter (-102
C>T) that alters the recognition sequence of the AP-2
transcription factor, leading to a reduction in transcriptional
activity. The aim of our study was to investigate possible
associations of the -102 C>T polymorphism with overall and
relapse-free breast cancer survival in a hospital-based case-only
study.
Materials and methods The relationship between the MnSOD
-102 C>T polymorphism and survival was examined in a cohort
of 291 women who received chemotherapy and/or radiotherapy
for incident breast cancer. The MnSOD -102 C>T genotype
was determined using a TaqMan allele discrimination assay.
Patient survival was evaluated according to the MnSOD
genotype using Kaplan–Meier survival functions. Hazard ratios
were calculated from adjusted Cox proportional hazards
modeling. All statistical tests were two-sided.
Results In an evaluation of all women, there was a borderline
significant reduction in recurrence-free survival with either one
or both variant alleles (CT + TT) when compared with patients
with wild-type alleles (CC) (odds ratio, 0.65; 95% confidence
interval, 0.42–1.01). When the analysis was restricted to
patients receiving radiation therapy, there was a significant
reduction in relapse-free survival in women who were
heterozygous for the MnSOD -102 genotype (relative risk, 0.40;
95% confidence interval, 0.18–0.86). Similarly, when the
homozygous and heterozygous variant genotypes were
combined, there remained a significant reduction in relapse-free
survival in this group (hazard ratio, 0.42; 95% confidence
interval, 0.20–0.87).
Conclusion The MnSOD -102 variant allele appears to be
associated with an improved recurrence-free survival in all
patients, and more dramatically in subjects who received
adjuvant radiation therapy.
Introduction
Breast cancer represents one of the most common cancers
among women residing in the United States and worldwide
[1,2]. In 2005, 145,920 US residents will be diagnosed with
breast cancer [3]. The etiological risk factors common to
breast cancer include age, personal or family history, obesity,
and lifetime exposure to exogenous and endogenous estro-
gens.
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Genetic risk factors have also been identified, such as the
high-penetrance cancer susceptibility genes, BRCA1  and
BRCA2, but these genes only account for 5% of all breast
cancer cases [4,5]. It has therefore been established that rel-
atively common genes acting together with endogenous/life-
style risk factors (low-penetrance genes) are likely to account
for a much higher portion of the breast cancer cases together
with as yet unidentified high-penetrance genes [6].
The development of breast cancer has been linked to the
degree of oxidative stress, particularly with perturbations in the
delicate balance between reactive oxygen species (ROS) and
oxidative defenses [7]. ROS are generated through the metab-
olism of estradiol, polyunsaturated fats, ethanol and calories,
all which have been considered potential risk factors for breast
cancer [8]. Antioxidant enzymes such as superoxide dis-
mutase have been demonstrated to protect cells from oxida-
tive stress. Generation of ROS has been implicated in the
etiology of a diversity of human diseases, including cancer [9].
Oxidative stress has been demonstrated to induce cell death
as a result of excessive cellular damage associated with lipid
peroxidation and alterations of nucleic acids and proteins, trig-
gering apoptosis through the mitochondria [10].
Superoxide dismutase catalyzes the dismutation of the super-
oxide radical (O2
-) to hydrogen peroxide (H2O2) and oxygen
(O2). Three distinct types of superoxide dismutases have been
identified in human cells: a homodimeric cytosolic CuZnSOD
[11], an extracellular homotetrameric glycosylated superoxide
dismutase [12], and a mitochondrial matrix homotetrameric
manganese superoxide dismutase (MnSOD) [13].
A specific region of the MnSOD protein is essential for the
correct transport and processing of MnSOD by mitochondria.
There have been conflicting reports of the association of the
polymorphism within the MnSOD mitochondrial targeting
sequence (-9 T>C; Val to Ala) and the risk of cancer. A signif-
icant gene dose-response relationship has been observed in
breast cancer [14,15]; however, more recent reports did not
find an association between -9 T>C MnSODand breast can-
cer [16-18].
Since radiation therapy remains an integral part of the multimo-
dality therapy in the treatment of breast cancer, determining
maximal efficacy among patients remains of the utmost impor-
tance. Radiation therapy exerts its antitumor effects through
the increased formation of ROS, including hydroxyl radicals
(OH), hydrogen peroxide (H2O2) and superoxide anions (O2
-),
and its efficacy may be related to the ability to neutralize these
effects. Because mitochondrial MnSOD is responsible for cat-
alyzing the conversion of superoxide radicals, there has been
a growing belief that gene variants could impact the efficacy of
radiation therapy for breast cancer. Similarly, the chemothera-
peutic agents most commonly utilized in the treatment of
breast cancer, adriamycin and cyclophosphamide, generate
ROS that may be effected by MnSOD activity. We recently
found that the combination of the MnSOD -9 genotype and
the myeloperoxidase genotype led to a threefold decrease in
the hazard of death among women treated for breast cancer
[19]. This association has further strengthened the need to
evaluate other possible gene variants that may play a role in
therapeutic efficacy.
The polymorphism in the signal sequence, a mutation in the
MnSOD promoter sequence (MnSOD -102 C>T) has been
shown to change the binding pattern of AP-2, leading to a
reduction in transcriptional activity [20]. We recently reported
that this polymorphism is relatively frequent in human popula-
tions [21,22]. A relationship between this polymorphism in the
MnSOD promoter and breast cancer treatment outcomes has
not, however, been reported. Similarly, there have been no
published reports of the effects the MnSOD -102 C>T poly-
morphism on protein function.
The aim of our study was therefore to investigate the possible
associations of the MnSOD -102 C>T polymorphism within a
case-only study of breast cancer patients to evaluate possible
associations with overall and relapse-free survival in relation to
the patients' adjuvant therapy.
Methods
Study subjects
As previously described [19,23], patients who received their
first course of adjuvant treatment for primary invasive breast
cancer at the Arkansas Cancer Research Center, University of
Arkansas for Medical Sciences from 1985 to 1996 were iden-
tified from hospital tumor registry records. Patients with a prior
history of cancer were excluded. Hospital tumor registry
records were used to obtain information concerning age,
stage at diagnosis, tumor size, tumor grade, hormone receptor
status, race, and date and type of therapy received (chemo-
therapy, radiotherapy, surgery, and hormonal treatment). The
hospital tumor registry was also the source of follow-up infor-
mation; the registry conducts active follow-up for each patient,
contacting the physician or the patient annually and recording
the date last contacted and the vital status. The study protocol
was approved by the Institutional Review Board of University
of Arkansas for Medical Sciences.
Archived normal lymph nodes or skin, stored in paraffin blocks
in the Pathology Department, were used as a source of DNA
for genotyping as described previously [19,23]. Hospital
tumor registry records identified 815 patients with invasive
breast cancer who had been treated at University of Arkansas
for Medical Sciences from 1985 to 1996. One hundred and
twenty-four (15%) of these patients had received no adjuvant
therapy (chemotherapy, radiation therapy, or tamoxifen)and
were excluded from the study, as were five (1%) patients with
missing adjuvant therapy information. Most of the excludedAvailable online http://breast-cancer-research.com/content/8/4/R45
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patients who did not receive adjuvant therapy had lymph node-
negative disease.
DNA extraction and genotyping
Sections (50 µm thick) were cut from archived paraffin normal
tissue blocks, the tissue was deparaffinized, and DNA was
extracted using a commercially available kit (Qiagen Inc.,
Valencia, CA, US), as previously described [19,23].
The MnSOD -102 C>T polymorphism was determined using
a technique developed in our laboratory [21]. Single nucle-
otide polymorphism-specific PCR primers and fluorogenic
probes were designed using Primer Express (version 1.5;
Applied Biosystems, Foster City, CA, USA). The fluorogenic
probes were labeled with a reporter dye (either FAM or VIC)
and are specific for one of the two possible bases (-102 C or
-102 T) in the MnSOD promoter region. TaqMan Universal
PCR Master Mix (Applied Biosystems) was used to prepare
the PCR. The two-times mix was optimized for TaqMan reac-
tions and contained AmpliTaq-Gold DNA polymerase, AmpEr-
ase, deoxyribonucleotide triphosphate with uracil
triphosphate, and a passive reference. Primers, probes, and
genomic DNA were added to final concentrations of 300 nM,
100 nM, and 0.5–2.5 ng/µl, respectively.
Controls (no DNA template) were run to ensure there was no
amplification of contaminating DNA. The amplification reac-
tions were carried out in an ABI Prism 7700 Sequence Detec-
tion System (Applied Biosystems) with two initial hold steps
Table 1
Demographic information and pathological characteristics of study participants and distribution of characteristics
n (%)
Age at diagnosis
≤50 years 133 (46)
>50 years 158 (54)
Race
Caucasian 239 (82)
African-American 52 (18)
Stage and node status
Stage 1 82 (28)
Stage 2 negative 57 (20)
Stage 2 positive 87 (30)
Stage 3 48 (16)
Stage 4 17 (6)
Estrogen receptor status
Positive 176 (64)
Negative 101 (36)
Progesterone receptor status
Positive 128 (46)
Negative 148 (54)
Treatment
Chemotherapy only 95 (33)
Radiation only 25 (9)
Chemotherapy/radiation 54 (19)
radiation/tamoxifen 36 (12)
Chemotherapy/tamoxifen 44 (16)
Chemotherapy/radiation/tamoxifen 35 (12)
Total n = 291.Breast Cancer Research    Vol 8 No 4    Martin et al.
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(50°C for 2 min, followed by 95°C for 10 min) and 50 cycles
of a two-step PCR (95°C for 15 s, 60°C for 1 min).
The fluorescence intensity of each sample was measured at
each temperature change to monitor amplification of the 278-
base-pair MnSOD promoter region. The -102 nucleotide was
determined by the fluorescence ratio of the two single nucle-
otide polymorphism-specific fluorogenic probes. The fluores-
cence signal increases when the probe with the exact
sequence match binds to the single-stranded template DNA
and is digested by the 5'-3' exonuclease activity of AmpliTaq-
Gold DNA polymerase (Applied Biosystems). Digestion of the
probe releases the fluorescent reporter dye (either FAM or
VIC) from the quencher dye.
Statistical analysis
Crude associations between genotypes for MnSOD and over-
all survival were evaluated using the Kaplan–Meier survival
function. The survival time was calculated as the time from
diagnosis to death or to the last contact date for living sub-
jects. Both heterozygotes and homozygotes were assessed
separately in relation to the referent. Cox proportional hazard
models were constructed to assess potential confounding
effects of other breast cancer prognostic factors, including
age, stage with nodal status, and estrogen and progesterone
receptor status. The final multivariate-adjusted models shown
include those factors that either changed the estimated effect
by 10% or more in a best-fitting model, which was developed
by starting with a full model and then excluding covariates that
did not improve the overall fit. Survival analysis according to
MnSOD  genotype was conducted separately by treatment
group (i.e. chemotherapy or radiation therapy). All analyses
were conducted using SAS software (version 8.2; SAS Insti-
tute, Inc., Cary, NC, USA). All statistical tests were two sided.
Results
Acceptable tissue samples and complete baseline information
were obtained for 291 cases (Table 1). A slight majority of
patients were older than 50 years of age (53%), with a small
percentage being of African-American decent (18%). There
was an even distribution of patients who were stage 1 (28%),
patients who were stage 2 lymph node negative (20%),
patients who were stage 2 lymph node positive (30%),
patients who were stage 3 (16%), and a smaller percentage
who were stage 4 (6%). Fifty-nine percent of estrogen recep-
tor-positive patients received tamoxifen therapy. A large per-
centage of patients received chemotherapy alone (33%),
when compared with those who received radiation alone (9%),
with those who received chemotherapy/radiation therapy
(19%), and with those who received other combinations
(Table 1).
Table 2
Manganese superoxide dismutase -102 genotype: overall and recurrence-free survivals
Genotype Cases Deaths Hazard ratio minimally adjusteda 
(95% confidence interval)
Hazard ratio fully adjustedb 
(95% confidence interval)
Overall survival 291 85 P for trend = 0.62 P for trend = 0.88
CC 180 55 1 (reference) 1 (reference)
CT 92 25 0.89 (0.55–1.43) 0.75 (0.465–1.24)
TT 19 5 0.88 (0.35–2.20) 1.06 (0.42–2.69)
CC 180 55 1 (reference) 1 (reference)
CT + TT 111 30 0.89 (0.57–1.38) 0.80 (0.50–1.28)
Recurrence-free survival 280c 100 P for trend = 0.12 P for trend = 0.08
CC 175 68 1 (reference) 1 (reference)
CT 87 28 0.77 (0.50–1.20) 0.65 (0.41–1.04)
TT 18 4 0.55 (0.20–1.50) 0.66 (0.24–1.83)
CC 175 68 1 (reference) 1 (reference)
CT + TT 105 32 0.73 (0.48–1.12) 0.65 (0.42–1.01)
CC, homozygous for the wild-type manganese superoxide dismutase gene; CT, heterozygous for the variant genotype; TT, homozygous for the 
variant genotype. aMinimally adjusted model: age. bFully adjusted model: age, stage with node status at diagnosis, race, estrogen receptor status, 
and progesterone receptor status. cEleven subjects were never disease free, thus they were deleted for recurrence-free survival.Available online http://breast-cancer-research.com/content/8/4/R45
Page 5 of 9
(page number not for citation purposes)
In patients with one or two copies of the variant MnSOD -102
(CT or TT), there was a nonsignificant impact of genotype on
overall survival (Table 2). Similarly, combining patients with
one or both variant alleles did not result in a significant change
in overall survival when compared with the reference genotype
(CC) (Figure 1a). In an evaluation of recurrence-free survival,
there was a trend towards significant improvement in recur-
rence-free survival in patients with one or two variant alleles
when compared with women homozygous for the common
allele (CC) (odds ratio, 0.65; 95% confidence interval, 0.42–
1.01) (Table 2). There was a trend towards an improvement in
recurrence-free survival with both homozygous (TT) and heter-
ozygous (CT) variant genotypes (Figure 1b).
Of the study population, there were 160 women who received
radiation therapy. Twenty-five patients received radiation
alone, 54 patients received radiation and chemotherapy, 46
patients received radiation and tamoxifen, and 35 patients
received radiation, chemotherapy, and tamoxifen.
In an evaluation of relapse-free survival in subjects receiving
radiation therapy there was a significant reduction in relapse-
free survival among women who were heterozygous for the
MnSOD -102 genotype (relative risk, 0.40; 95% confidence
interval, 0.18–0.86) (Table 3). When the homozygous and het-
erozygous variant alleles were combined, there remained a
significant reduction in relapse-free survival in this group (Fig-
ure 2).
There were 230 patients in the study population who received
chemotherapy. Among these women, there was an associa-
tion of borderline significance between MnSOD genotypes
and relapse-free survival (adjusted hazard ratio for CT + TT
genotype, 0.65; 95% confidence interval, 0.40–1.05) (Table
4). There were, however, no significant associations with over-
all survival.
Figure 1
(a) Percentage overall survival and (b) percentage recurrence-free sur- vival by years of follow-up in the manganese superoxide dismutase - 102 genotype (a) Percentage overall survival and (b) percentage recurrence-free sur-
vival by years of follow-up in the manganese superoxide dismutase -
102 genotype. CC, homozygous wild-type genotype; CT, heterozygous 
for variant genotype; TT, homozygous variant genotype.
Figure 2
The manganese superoxide dismutase -102 genotype: (a) percentage  overall survival and (b) percentage recurrence-free survival by years of  follow-up with radiation therapy The manganese superoxide dismutase -102 genotype: (a) percentage 
overall survival and (b) percentage recurrence-free survival by years of 
follow-up with radiation therapy. CC, homozygous wild-type genotype; 
CT, heterozygous for variant genotype; TT, homozygous variant geno-
type.Breast Cancer Research    Vol 8 No 4    Martin et al.
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Table 3
Manganese superoxide dismutase -102 genotype: overall and recurrence-free survivals with radiation therapy
Genotype Cases Deaths Hazard ratio minimally adjusteda 
(95% confidence interval)
Hazard ratio fully adjustedb 
(95% confidence interval)
Overall survival 150 33 P for trend = 0.67 P for trend = 0.91
CC 93 20 1 (reference) 1 (reference)
CT 51 11 0.97 (0.46–2.04) 0.74 (0.35–1.58)
TT 6 2 1.95 (0.45–8.49) 2.23 (0.46–10.79)
CC 93 20 1 (reference) 1 (reference)
CT + TT 57 13 1.05 (0.52–2.12) 0.82 (0.40–1.70)
Recurrence-free survival 145 40 P for trend = 0.14 P for trend = 0.03
CC 90 29 1 (reference) 1 (reference)
CT 50 10 0.57 (0.28–1.18) 0.40 (0.18–0.86)
TT 5 1 0.60 (0.08–4.47) 0.69 (0.09–5.46)
CC 90 29 1 (reference) 1 (reference)
CT + TT 55 11 0.57 (0.28–1.16) 0.42 (0.20–0.87)
CC, homozygous for the wild-type manganese superoxide dismutase gene; CT, heterozygous for the variant genotype; TT, homozygous for the 
variant genotype. aMinimally adjusted model: age. bFully adjusted model: age, stage with node status at diagnosis, race, estrogen receptor status, 
and progesterone receptor status.
Table 4
Manganese superoxide dismutase -102 genotype: overall and recurrence-free survivals with adjuvant chemotherapy
Genotype Cases Deaths Hazard ratio minimally adjusteda 
(95% confidence interval)
Hazard ratio fully adjustedb (95% 
confidence interval)
Overall survival 230 75 P for trend = 0.46 P for trend = 0.42
CC 140 49 1 (reference) 1 (reference)
CT 73 21 0.83 (0.49–1.38) 0.67 (0.38–1.17)
TT 17 5 0.81 (0.32–2.04) 1.07 (0.42–2.74)
CC 140 49 1 (reference) 1 (reference)
CT + TT 90 26 0.82 (0.51–1.33) 0.73 (0.44–1.22)
Recurrence-free survival 220 85 P for trend = 0.16 P for trend = 0.12
CC 136 57 1 (reference) 1 (reference)
CT 68 24 0.79 (0.49–1.28) 0.64 (0.38–1.07)
TT 16 4 0.55 (0.20–1.52) 0.73 (0.26–2.049)
CC 136 57 1 (reference) 1 (reference)
CT + TT 84 28 0.75 (0.47–1.18) 0.65 (0.40–1.05)
CC, homozygous for the wild-type manganese superoxide dismutase gene; CT, heterozygous for the variant genotype; TT, homozygous for the 
variant genotype. aMinimally adjusted model: age. bFully adjusted model: age, stage with node status at diagnosis, race, estrogen receptor status, 
and progesterone receptor status.Available online http://breast-cancer-research.com/content/8/4/R45
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Discussion
In this evaluation of the effects of the MnSOD -102 polymor-
phism on survival after treatment for breast cancer, we found
that women with genotypes that would result in less MnSOD
expression, and thus higher levels of ROS, had a significant
decrease in relapse-free survival among breast cancer sub-
jects who received adjuvant radiation therapy as well as chem-
otherapy. There was also a trend toward decreased overall
relapse-free survival in all subjects with breast cancer. This
study further indicates that genetic variants that may result in
decreased function, and thus increased oxidative stress, may
enhance the efficacy of radiation therapy and thus translate
into better disease control. This is the first study to examine the
relationship between the MnSOD -102 genotype and the sur-
vival of breast cancer patients treated with adjuvant therapy.
These results support the our previous findings that demon-
strated a decrease in the hazard of death with the MnSOD -9
CC and MPO GG genotypes [19]. In that analysis, genotypes
associated with higher levels of ROS for women with breast
cancer treated with adjuvant therapy led to improved overall
survival when compared with women with lower levels of ROS.
Our results also add to the already large volume of literature
on the role of the mitochondrial MnSOD in cancer cell survival.
Evaluation of MnSOD suggests that it is critically important in
maintenance of mitochondrial function. Mice with deficiency of
this enzyme exhibit progressive cardiomyopathy, neurodegen-
eration, and perinatal death [24]. These studies also confirmed
that transgenic mice that express human MnSOD in the mito-
chondria are protected from environmental oxygen-induced
lung injury [25] and adriamycin-induced cardiac toxicity [26].
In contrast, disruption of the other two superoxide dismutases
yielded viable mice that were normal in nonstressful conditions
[27]. The mitochondrial MnSOD therefore represents a major
cellular defense against oxidative stress.
Additional clinical studies have evaluated MnSOD expression
with conflicting results. Janssen and colleagues [28] evalu-
ated 81 gastric adenocarcinomas and found a significantly
higher MnSOD expression within the tumor when compared
with the normal mucosa. This higher expression did not corre-
late to a worse outcome; however, the ratio of MnSOD expres-
sion of tumor compared with the normal tissue was correlated
with a worse overall survival. The significance of this upregula-
tion and worse outcome was felt to be related to chemoresist-
ance but was not elucidated in this study.
A study by Malafa and colleagues [29] reported the difference
in MnSOD expression in gastric carcinoma for metastatic and
nonmetastatic cancers. Although the nonmetastatic gastric
cancers showed no increase in expression versus normal gas-
tric epithelial cells, 93% of primary tumor cells of metastatic
gastric cancer cells showed an upregulation of MnSOD enzy-
matic activity. This correlation of increased MnSOD expres-
sion and increased metastatic prevalence correlates with the
theory that MnSOD's role changes during the transformation
of a cell from normal to dysplasia to cancer. MnSOD initially
appears to acts as a tumor suppressor by inhibiting the ROS
and preventing cellular damage; however, once the transfor-
mation to malignant cells has taken place, the results of several
studies infer that the MnSOD acts to protect the malignant cell
both from chemotherapy [28,30] and from radiation therapy
[31,32] to allow for its progression, replication, and metasta-
sis. This can be explained by the fact that the defenses against
malignant cells, whether the body's host defenses or exoge-
nous treatments such as radiation or chemotherapy, often use
ROS as a mechanism for cellular destruction. Malignant cells
that have an increased expression of MnSOD would therefore
be more resistant to cellular destruction and would therefore
more probably be resistant to treatment. This increase in
MnSOD expression would lead to an increase in the probabil-
ity of proliferation and metastasis.
The theory has been strengthened by Izutani and colleagues'
[31] demonstration of the role of MnSOD after progression to
cancer. An upregulation of MnSOD mRNA in gastric carci-
noma was demonstrated, which provided a protective mecha-
nism from the cell toxicity of tumor necrosis factor alpha from
ROS. Izutani and colleagues' [32] later report confirmed these
findings by demonstrating an upregulation of MnSOD mRNA
in squamous esophageal carcinoma. This upregulation of
MnSOD mRNA in active malignant cells not only acts to pro-
tect from the body's host defensive mechanisms, but a recent
report by Hur and colleagues [30] demonstrated that MnSOD
upregulation also gives gastric cancers protection against cur-
rent chemotherapy agents. Further research by Izutani and col-
leagues [33] indicated that MnSOD expression inhibited the
tumor sensitivity of adriamycin in esophageal and gastric can-
cers. Furthermore, use of transforming growth factor beta to
inhibit MnSOD showed an increase in the effectiveness of
adriamycin as a suppressor of these tumors [33]. Not only
does this research solidify the theory that MnSOD protects the
tumor cells after their transformation, but it leads us to believe
that, by inhibiting MnSOD, chemotherapy may be made more
effective.
Our results are in contrast to a smaller study (n = 80) of
women receiving radiation therapy for breast cancer, who
found no effects of the MnSOD -9 polymorphisms on clinically
detectable skin reactions to therapy [34]. These discrepant
results may be due to more dominant effects that the MnSOD
-102 polymorphism plays in MnSOD function, or could be due
to differential effects of MnSOD variability on normal and
tumor tissue or, finally, could be due to the small number of
subjects (n = 80) in the study. Since the MnSOD -9 polymor-
phism leads to partial inner mitochondrial membrane transport
arrest [35], there have been conflicting reports as to which
polymorphism (c allele = alanine or t allele = valine) leads to
the greater risk of cancer. Since the MnSOD -102 polymor-Breast Cancer Research    Vol 8 No 4    Martin et al.
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phism affects the AP-2 binding and thus reduces transcrip-
tional activity, however, there may be a greater effect from this
polymorphism than from other polymorphisms that have been
reported.
Even with this report indicating the efficacy effects of ROS
producing therapies and the relationship to MnSOD polymor-
phisms, this initial evaluation needs to be replicated in a larger
study, with greater homogeneity of the subject population.
Since very little is know about the clinical effects of the
MnSOD -102 polymorphism in carcinogenesis, tumor cell
resistance and chemotherapy/radiation therapy efficacy, fur-
ther evaluation is needed. Because this study involved women
who received various adjuvant treatments (radiation, chemo-
therapy and/or hormonal therapy), we are unable to establish
the effects that each individual therapy had on overall survival
and on relapse-free survival. Since there is a similarity in the
effects that chemotherapy in breast cancer treatment and radi-
ation therapy induce (generation of ROS), however, it is less
likely that individual treatment evaluation will lead to different
results. Radiation therapy and the chemotherapeutic agents
most commonly utilized in the treatment of breast cancer, adri-
amycin and cyclophosphamide, exert their antitumor effects
through the increased formation of ROS, including hydroxyl
radicals (OH), hydrogen peroxide (H2O2), and superoxide ani-
ons (O2
-), and the efficacy may be related to the ability of the
patients'/tumors' ability to neutralize these effects. Since
MnSOD is not involved in the metabolism of any specific
chemotherapeutic agent we believe these results will remain
consistent, but they need to be evaluated in a larger study.
Conclusion
In summary, this reports demonstrates the first evaluation that
decreases in MnSOD by the variant genotype are associated
with improved relapse-free survival in women treated for
breast cancer.
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